NCT03018067View on ClinicalTrials.gov

A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia

PHASE2TerminatedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

May 31, 2017

Study Completion Date

May 31, 2017

Conditions
Hyperkalemia
Interventions
DRUG

RDX227675

DRUG

Placebo

Trial Locations (1)

27511

Capital Nephrology Associates, PA, Cary

Sponsors

Lead Sponsor

Ardelyx
All Listed Sponsors
lead

Ardelyx

INDUSTRY